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Introduction {#sec1}
============

Post-synthesis covalent modification of biological molecules is a key aspect of intracellular signaling, and it is critically important in many biological processes. RNA molecules, similar to proteins, are subject to a vast array of post-synthesis covalent modifications, which together constitute the epitranscriptome. To date, \>100 RNA modifications have been identified, which are spread throughout every class of RNA and are evolutionarily conserved throughout all kingdoms of life ([@bib10], [@bib45]).

RNA modifications have the potential to affect all RNA processes, including splicing, stability, and localization ([@bib54]). Many RNA modifications have been identified by mass spectrometry (MS), and complex epitranscriptomes of tRNA and rRNA have been thoroughly studied. However, this represents a mere snapshot of a much bigger picture, with the clear majority of modifications remaining uncharacterized. This is predominantly due to a lack of sensitive methodologies with which to detect the modifications at a high resolution. Even now, MS methodologies are largely unable to generate transcriptome-wide modification profiles. However, a few very recent analyses have used anti-modification antibodies (e.g., against N1-methyladenosine \[[@bib20]\], N6-methyladenosine \[[@bib19]\], and 5-hydroxymethylcytosine \[[@bib17]\]) or chemical reactivity of the modification (for pseudouridine \[[@bib11], [@bib56]\], m~5~C \[[@bib55]\], and 2′-O-methylation \[[@bib15]\]). Their results clearly suggest that many of the modifications identified on rRNA and tRNA are also present on other RNA classes. Therefore, the development of epitranscriptomic methodologies (e.g., new antibody and chemical methods coupled to next-generation sequencing \[NGS\]) represents a bottleneck in deciphering the function of new RNA modifications.

Certain nucleotides, such as 7-methylguanosine (m7G), display specific modification-dependent chemistries that can be exploited to study their prevalence and transcript location. m7G is present in eukaryotic mRNA 5′ caps and at defined internal positions within tRNAs and rRNAs across all domains of life. The best-characterized enzyme mediating internal m7G methylation is the TRMT8 yeast enzyme homolog METTL1 (methyltransferase-like 1), which, together with its co-factor WDR4 (WD repeat domain 4), catalyzes m7G at G46 of specific tRNAs, such as tRNA^Phe^ ([@bib2]).

In contrast to deoxy-m7G, m7G in RNA is highly stable in neutral aqueous solution ([@bib30]). The methylation significantly alters the charge density of RNA, potentially serving as a molecular handle, but it does not impair Watson-Crick G:C base complementarity. It does, however, interfere with non-canonical base pairing (i.e., Hoogsteen pairs), possibly affecting the secondary structure of RNA. Although relatively abundant, m7G has proved very difficult to study so far. Being neutral to Watson-Crick base pairing, it does not interfere with reverse transcription, rendering it invisible to detection by standard sequencing-based technologies.

microRNAs (miRNAs) are short single-stranded RNA molecules (18--24 nucleotides \[nt\]) that target the RNA interference silencing complex (RISC) to specific mRNAs. Their specificity is mediated by partial base pairing to sequences predominantly found in the 3′ UTR of mRNAs ([@bib5]). This interaction results in the decreased translation of the proteins they encode and/or in the degradation of the mRNAs themselves ([@bib23], [@bib25]). To date, \>1,000 human miRNAs have been identified, and they are key regulators of numerous physiological and pathological processes.

miRNA biosynthesis is complex and involves a multistep pathway that can be regulated at many levels ([@bib6]), including post-transcriptional modification of miRNA precursors ([@bib1], [@bib63]). miRNAs are synthesized from larger transcripts by RNA polymerase II or III. These primary miRNA transcripts (pri-miRNAs) are then cleaved by DROSHA to release hairpin-shaped RNAs called pre-miRNAs ([@bib37]), and further cleaved by DICER to generate a miRNA duplex ([@bib14]). Certain miRNAs can form alternative secondary structures, such as G-quadruplexes, that can interfere with their processing ([@bib48], [@bib50]). However, little is known about the biological relevance of these structures in a physiological context.

Here, we develop two different but complementary high-throughput sequencing strategies to identify miRNAs harboring internal m7G modification. We show that METTL1 methylates a specific subset of tumor suppressor miRNAs, including *let-7*, to promote their processing from primary transcript to precursor miRNA. Depletion of METTL1 causes gene expression and phenotypic changes in a miRNA-dependent manner. We show that m7G-modified miRNAs have a propensity to form G-quadruplexes. We identify guanosine 11 as the m7G methylated residue within *let-7e-5p*, and we show that methylation at this position affects G-quadruplex formation, thereby promoting processing of the precursor miRNA.

Results {#sec2}
=======

To detect N7-methylguanosine within low-abundant RNAs, we adapted an existing strategy ([@bib65]) to allow the profiling of internal m7G in eukaryotic RNAs. In this reaction, m7G residues are prone to nucleoside hydrolysis when reduced by treatment with NaBH~4~. The resulting abasic sites can be revealed by aniline-induced cleavage of the RNA chain by β-elimination. This reaction is the basis of direct RNA sequencing (RNA-seq) by the Maxam and Gilbert method ([@bib51]) and has been used for mapping m7G residues in highly abundant rRNAs and tRNAs at single nucleotide resolution ([@bib65]). We optimized the reaction conditions for the reduction of mammalian total RNA in the absence of methylated carrier RNA, which would interfere with the NGS analysis. As proof of principle, reduced *18S* rRNA was cleaved by aniline treatment into two fragments, in agreement with the known position of m7G ([@bib52]; [Figure S1](#mmc1){ref-type="supplementary-material"}A).

The above strategy is not suitable for very short RNAs such as miRNAs, because the resulting cleavage fragments would be too small to be unequivocally mapped to the human transcriptome. Therefore, we developed a new protocol, based on the above, to detect m7G within miRNAs, which we refer to as Borohydride Reduction (BoRed-seq) ([Figure 1](#fig1){ref-type="fig"}A). Total RNA from a human lung cancer cell line (A549 cells) was decapped, treated with NaBH~4~, and exposed to low pH to generate abasic sites at positions harboring m7G. These sites were exposed to a biotin-coupled aldehyde reactive probe (*N*-(aminooxyacetyl)-*n*′-([d]{.smallcaps}-biotinoyl) hydrazine; ARP) that covalently binds to abasic RNA sites ([@bib60]). Modified RNAs were then pulled down using streptavidin beads, small RNA libraries were prepared, and RNAs were identified by high-throughput sequencing. Using this approach ([Figure 1](#fig1){ref-type="fig"}B), a number of mature miRNAs likely to contain m7G were identified ([Table S1](#mmc2){ref-type="supplementary-material"}).Figure 1Detection of m7G in Specific miRNAs in A549 Cells(A) Schematic of a novel chemical method to detect internal m7G RNA modification.(B) Schematic representation of the procedure used to identify the m7G modified miRNAs in A549 cells.(C) Immuno-dot blot of total decapped INPUT RNA (10%) or RNA immunoprecipitated with anti-m7G antibody or control immunoglobulin G (IgG).(D) Immunoprecipitation with anti-m7G antibody enriches for m7G-containaing RNAs as determined by mass spectrometry (MS; see also [Figure S1](#mmc1){ref-type="supplementary-material"}). The average of two biological replicates ± SDs is shown.(E) Scatterplot showing a high degree of consistency between the BoRed-seq approach and RIP-seq in detecting miRNAs harboring m7G (upper right quadrant). Goodness of fit is calculated as R^2^ Pearson correlation coefficient.(F) RNA immunoprecipitation with the anti-m7G antibody coupled to qRT-PCR was used to validate five m7G-containing miRNAs and four negative miRNAs, which are identified in (E). The average of four biological replicates ± SDs is shown. The distributions of mean enrichments in m7G^+^ and m7G^−^ miRNAs are significantly different, as evaluated by the two-tailed Wilcoxon text (^∗^p \< 0.05).(G) Venn diagram showing the overlap between miRNAs significantly enriched in m7G-RIP of A549 and Caco-2 cells, respectively (see also [Figure S2](#mmc1){ref-type="supplementary-material"}). The p value is obtained by Fisher's exact test.(H) Western blot showing METTL1 protein levels in A549 cells infected with *METTL1*-specific (sh1, sh2) or control (Scramble) tetracycline (TET)-inducible shRNAs 5 days after doxycycline treatment. A representative experiment of four independent biological replicates is shown.(I) Boxplot showing increased m7G signal (as an average enrichment in both BoRed-seq and m7G-RIP-seq; E) in miRNAs that are significantly downregulated (↓) upon inducible *METTL1* knockdown, but not in miRNAs that are unchanged (=) or upregulated (↑). Statistical significance was calculated by the Wilcoxon test.(J) qRT-PCR showing the levels of *let-7e-5p* and *miR-125a-5p* in WT and *METTL1* knockdown A549 cells in the presence of either active (+) or catalytically inactive (c.i.) exogenous METTL1 (Ex. METTL1).

To confirm the validity of this technique and to provide an independent verification of m7G-methylated miRNAs, we performed an RNA immunoprecipitation sequencing (RIP-seq) experiment using an antibody that recognizes m7G in RNA ([Figure 1](#fig1){ref-type="fig"}C). This antibody immunoprecipitates m7G-containing RNAs, but not other methylated G-containing RNAs (as judged by MS; [Figures 1](#fig1){ref-type="fig"}D and [S1](#mmc1){ref-type="supplementary-material"}B--S1D), and it specifically enriches m7G-containing *18S* rRNA and tRNAs ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). RIP-seq with this antibody identified a second cohort of mature miRNAs containing m7G ([Table S2](#mmc3){ref-type="supplementary-material"}).

We then compared the results from the BoRed-seq and RIP-seq approaches and found there was a significant overlap of m7G-modified miRNAs detected by each technique ([Figures 1](#fig1){ref-type="fig"}E, upper right quadrant, [S2](#mmc1){ref-type="supplementary-material"}C, and [S2](#mmc1){ref-type="supplementary-material"}D). We regard these miRNAs as high-confidence m7G-modified miRNAs ([Table S3](#mmc4){ref-type="supplementary-material"}), five of which were validated by RIP-qPCR analysis ([Figure 1](#fig1){ref-type="fig"}F). m7G is found on miRNAs of any abundance, bearing no correlation with any particular expression level ([Figure S2](#mmc1){ref-type="supplementary-material"}E).

We extended these analyses to an unrelated colorectal cancer cell line (Caco-2 cells), which expresses METTL1 at levels comparable to those observed in A549 cells. This identified significantly overlapping m7G-modified miRNAs ([Figures 1](#fig1){ref-type="fig"}G and [S2](#mmc1){ref-type="supplementary-material"}F; [Table S4](#mmc5){ref-type="supplementary-material"}), suggesting that m7G modification of miRNAs is a general and conserved phenomenon.

Deposition of m7G in tRNA is catalyzed, at least in part, by METTL1. We therefore asked whether any of our high-confidence m7G-containing miRNAs are affected by METTL1 depletion. Knockdown of *METTL1* in A549 cells ([Figures 1](#fig1){ref-type="fig"}H and [S2](#mmc1){ref-type="supplementary-material"}G) followed by small RNA-seq revealed that significantly downregulated miRNAs are more enriched in m7G, compared to miRNAs that are upregulated or unchanged ([Figure 1](#fig1){ref-type="fig"}I; [Table S5](#mmc6){ref-type="supplementary-material"}). Similar effects were also observed in Caco-2 cells ([Figure S2](#mmc1){ref-type="supplementary-material"}H). The reduced levels of m7G-containing miRNAs are rescued by the expression of wild-type (WT) METTL1 but not by a catalytically inactive version ([Figures S2](#mmc1){ref-type="supplementary-material"}I and S2J) of the enzyme ([Figure 1](#fig1){ref-type="fig"}J).

Interrogation of the m7G-containing miRNAs downregulated upon *METTL1* knockdown ([Table 1](#tbl1){ref-type="table"}) shows that 50% (10/20) of them have been previously functionally linked to the inhibition of cell migration ([@bib64]). This raised the possibility that METTL1 may control cell migration via regulation of a subset of miRNAs, including the *let-7* family ([@bib35]). To explore this possibility, we first tested whether METTL1 affects the migration of A549 cells. Knockdown of *METTL1* significantly increases their migratory capacity ([Figures 2](#fig2){ref-type="fig"}A and 2B) without affecting cellular proliferation ([Figure 2](#fig2){ref-type="fig"}C) or overall mRNA translation levels ([Figure S2](#mmc1){ref-type="supplementary-material"}K). Notably, the increased migration is rescued by the expression of WT METTL1, but not by a catalytically inactive version of the enzyme ([Figure S3](#mmc1){ref-type="supplementary-material"}A). These results suggest that METTL1 specifically influences cell migration via m7G methylation of miRNAs.Table 1miRNAs Harboring METTL1-Dependent m7GBoRed-Seqm7G-RIP-SeqmiRNALog2EnrichFDRLog2EnrichFDR*hsa-let-7a-5p*^*(im)*^3.7931.47E−350.9237.05E−12*hsa-let-7b-3p*3.6505.36E−200.9231.26E−11*hsa-let-7b-5p*^*(im)*^3.8485.38E−401.7561.25E−27*hsa-let-7c-5p*^*(im)*^4.0496.87E−391.1284.61E−15*hsa-let-7e-5p*^*(im)*^3.3575.77E−302.1496.00E−32*hsa-miR-125a-5p*^*(im)*^0.9213.76E−030.5753.46E−03*hsa-miR-149-3p*3.2272.37E−022.3063.03E−14*hsa-miR-193a-5p*1.6738.71E−030.7439.27E−04*hsa-miR-23b-5p*^*(im)*^2.4906.78E−062.7893.32E−54*hsa-miR-320a*^*(im)*^1.9244.26E−111.3361.07E−14*hsa-miR-320b*^*(im)*^2.5686.54E−161.7407.94E−54*hsa-miR-320c*^*(im)*^3.4651.81E−202.0663.88E−50*hsa-miR-320d*2.9681.84E−092.2174.53E−59*hsa-miR-320e*2.7941.15E−021.4601.89E−09*hsa-miR-328-3p*1.6698.85E−031.2602.17E−15*hsa-miR-505-5p*2.8303.12E−022.2741.52E−13*hsa-miR-663a*^*(im)*^6.6713.23E−431.1067.60E−04*hsa-miR-760*3.1425.18E−042.2581.93E−31*hsa-miR-92b-3p*2.4167.64E−141.4591.72E−27*hsa-miR-92b-5p*4.3021.06E−300.8051.84E−07[^5]Figure 2METTL1 Inhibits Cellular Migration of A549 Cells(A) A migration assay was performed for 7 h using cells infected with *METTL1*-specific (sh1, sh2) or control (Scramble) TET-inducible shRNAs 5 days after doxycycline treatment.(B) Results from (A) were quantitated and plotted, as indicated. The plot shows the average of six biological replicates ± SDs (^∗∗∗^p \< 0.001, two-tailed t test).(C) A proliferation assay was initiated 4 days after doxycycline treatment of cells infected with *METTL1*-specific (sh1, sh2) or control (Scramble) TET-inducible shRNAs. The average of four biological replicates ± SDs is shown.(D) Global gene expression analysis of cells infected with *METTL1*-specific (sh1) or control (Scramble) TET-inducible shRNAs 5 days after doxycycline treatment. log~2~ fold change was plotted against average log~2~ expression. Significantly upregulated (red) and significantly downregulated (blue) transcripts are indicated. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.(E) Gene Ontology analysis of gene expression changes following *METTL1* knockdown identifying upregulated Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways involved in cellular migration (red).(F) log~2~ fold change in the expression of predicted targets of the indicated miRNAs upon *METTL1* knockdown. Each pair of boxplots compares the fold change of mRNAs that are targets (red) or not (gray) of a single specific miRNA. Statistical significance was calculated by the Wilcoxon test.

To further explore this possibility, we performed a global gene expression analysis to identify transcripts affected by the depletion of METTL1 ([Figure 2](#fig2){ref-type="fig"}D; [Table S6](#mmc7){ref-type="supplementary-material"}). This revealed 254 upregulated and 60 downregulated transcripts. Gene Ontology analysis indicated the upregulation of pathways involved in cellular migration ([Figures 2](#fig2){ref-type="fig"}E, and [S4](#mmc1){ref-type="supplementary-material"}B--S4E; [Table S7](#mmc8){ref-type="supplementary-material"}), in agreement with our phenotypic characterization of *METTL1* knockdown cells ([Figures 2](#fig2){ref-type="fig"}A and 2B).

We then asked whether METTL1-regulated transcripts are also targets of the m7G-modified miRNAs. *In silico*-predicted mRNA targets for these miRNAs are differentially expressed upon *METTL1* knockdown, whereas mRNA targets of control miRNAs are not ([Figure 2](#fig2){ref-type="fig"}F). We confirmed these findings using an unbiased approach that identified *let-7(5p)* seed sequence as the most significantly enriched in upregulated mRNAs ([Figure S3](#mmc1){ref-type="supplementary-material"}F), a number of which are individually shown in [Figure S3](#mmc1){ref-type="supplementary-material"}G. The presence of the *let-7* target sequence within the 3′UTR of mRNAs represents the strongest predictive factor for their upregulation upon *METTL1* knockdown ([Figure S3](#mmc1){ref-type="supplementary-material"}H).

The above results indicate that many of the genes involved in cell migration and upregulated upon METTL1 depletion are targets of METTL1-dependent miRNAs. This suggests that METTL1 regulates gene expression via the control of miRNA function. To investigate this possibility, we focused on *HMGA2,* one of the most upregulated transcripts following METTL1 depletion, and whose 3′ UTR is significantly enriched for evolutionarily conserved target sites of several m7G-containing miRNAs, including *let-7(5p)*, *miR-125(5p)*, and *miR-92(3p)* ([Figure 3](#fig3){ref-type="fig"}A; odds ratio \[OR\] = 5.46, p = 0.001). First, we confirmed that *METTL1* knockdown increases *HMGA2* mRNA expression and protein levels in both A549 cells ([Figures 3](#fig3){ref-type="fig"}B and 3C) and Caco-2 cells ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B). Second, we confirmed that *HMGA2* mRNA is not m7G modified itself by performing BoRed-qPCR and RIP-qPCR ([Figure S4](#mmc1){ref-type="supplementary-material"}C).Figure 3METTL1 Catalytic Activity Regulates *HMGA2* Expression in a *let-7-*Dependent Manner(A) Schematic of *HMGA2* 3′ UTR showing the enrichment of evolutionarily conserved target sites of several m7G-containing miRNAs (OR = 5.46, p = 0.001).(B) *HMGA2* expression was measured by qRT-PCR in A549 cells infected with *METTL1*-specific (sh1, sh2) or control (Scr) TET-inducible shRNAs 5 days after doxycycline treatment. The average of six biological replicates ± SDs is shown (^∗∗∗^p \< 0.001, two-tailed t test).(C) Western blot showing METTL1, HMGA2, and β-tubulin protein levels in A549 cells infected with *METTL1*-specific (sh1, sh2) or control (Scramble) TET-inducible shRNAs 5 days after doxycycline treatment. Two representative biological replicates of a total of four are shown.(D) Western blot showing METTL1 downregulation upon transfection with *METTL1*-specific siRNAs in A549 cells stably expressing a luciferase cDNA with *Hmga2* 3′ UTR. Two independent transfections of a total of four replicates are shown.(E) Luciferase fluorescence levels upon *METTL1* downregulation in A549 cells stably expressing a luciferase cDNA with *Hmga2* 3′ UTR as a reporter. Red and gray bars indicate luciferase levels in the presence of either WT *Hmga2* 3′ UTR or of a variant in which all 7 *let-7* seed sequences have been mutated, respectively. The plot shows the average of four independent transfections ± SDs (^∗∗∗^p \< 0.001, two-tailed t test).(F) Western blot showing the rescue of HMGA2 upregulation upon transfection with *let-7e-5p* mature miRNA in *METTL1* knockdown A549 cells. Two independent transfection replicates of a total of four are shown.(G) Western blot showing the rescue of HMGA2 upregulation upon the overexpression of WT, but not catalytically inactive METTL1, in A549 *METTL1* knockdown cells. Two representative biological replicates of a total of five independent infections are shown.See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

To demonstrate that the effect of METTL1 was mediated, at least in part, by a miRNA pathway, we generated a stable A549 cell line containing a reporter construct consisting of the 3′ UTR of *Hmga2* linked to the coding sequence of luciferase. Knock down of *METTL1* in this reporter line increases luciferase activity, confirming that the 3′ UTR of *HMGA2* confers responsiveness to METTL1 ([Figures 3](#fig3){ref-type="fig"}D and 3E). To confirm that METTL1 regulation of the 3′ UTR of *HMGA2* is mediated through the action of miRNAs, we concentrated on *let-7*, which has seven binding sites within this 3′ UTR. Deletion of the *let-7* seed sequences from the 3′ UTR leads to increased luciferase activity and uncouples it from METTL1 regulation ([Figures 3](#fig3){ref-type="fig"}E and [S4](#mmc1){ref-type="supplementary-material"}D).

[Figure 3](#fig3){ref-type="fig"}F shows that the introduction of mature *let-7e-5p* miRNA into A549 cells reduced HMGA2 protein expression as expected ([@bib46]). Transfection of mature *let-7e* miRNA reverts the upregulation of HMGA2 protein caused by METTL1 depletion ([Figure 3](#fig3){ref-type="fig"}F). Expression of a short hairpin RNA (shRNA)-resistant version of WT METTL1 also reverts HMGA2 upregulation due to METTL1 depletion, and this requires the catalytic activity of the methyltransferase ([Figure 3](#fig3){ref-type="fig"}G). These data confirm that METTL1 methyltransferase activity regulates the expression of *HMGA2* in a *let-7-*dependent manner.

We next explored the functional role of *let-7* methylation by METTL1. We used UV cross-linking and immunoprecipitation (CLIP) to confirm in our system previous findings ([@bib4]) that METTL1 binds directly to miRNA precursors, including *pri-let-7e* and *pri-miR-125a* hairpins ([Figures 4](#fig4){ref-type="fig"}A and [S4](#mmc1){ref-type="supplementary-material"}E). To date, there are two known methylations of miRNA: m6A catalyzed by METTL3 ([@bib1]) and 5′-phosphate methylation catalyzed by BCDIN3D ([@bib63]). In both cases, methylation regulates miRNA processing. To test whether METTL1 may also be involved in such a pathway, we asked whether it regulates the processing of m7G-containing miRNAs. Depletion of METTL1 significantly reduced the levels of the premature and mature forms of *let-7e-5p* and *miR-125a-5p*, whereas their primary transcripts were unaffected ([Figures 4](#fig4){ref-type="fig"}B, 4C, and [S4](#mmc1){ref-type="supplementary-material"}F). This is unlikely to be due to a general defect in processing since METTL1 depletion does not affect the levels of various miRNA processing factors ([Figure S4](#mmc1){ref-type="supplementary-material"}G).Figure 4METTL1 Directly Modifies *let-7e* pri-miRNA and Regulates Its Processing(A) CLIP-qPCR using a METTL1-specific antibody or a non-specific IgG. The levels of immunoprecipitated *pri-let-7e* and *pri-mir-125a* hairpins are shown. The average of two independent immunoprecipitation reactions ± SEMs is shown (^∗^p \< 0.05, two-tailed t test). *miR-148a* is shown in [Figure S4](#mmc1){ref-type="supplementary-material"}E as a negative control.(B) qRT-PCR showing the levels of either *LET7E/125A* primary transcript (blue) or *let-7e* and *miR-125a* precursors (gray) upon *METTL1* knockdown in A549 cells. The average of five to six independent biological replicates ± SDs is shown (^∗^p \< 0.05, ^∗∗^p \< 0.01, two-tailed t test).(C) qRT-PCR quantification of *let-7e-5p* and *miR-125a-5p* upon *METTL1* knockdown. The average of five independent biological replicates ± SDs is shown (^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, two-tailed t test). *miR-148a-3p* is shown in [Figure S4](#mmc1){ref-type="supplementary-material"}F as a negative control.(D) m7G RNA immunoprecipitation and qRT-PCR of *LET7A3*, *LET7B*, and *LET7E/125A* primary transcripts in A549 cells upon *METTL1* knockdown. The average of three independent biological replicates ± SEMs is shown (^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, two-tailed t test).(E) *In vitro* methylation reaction using recombinant METTL1/WDR4 pre-assembled complex on *let-7e* or *cel-miR-67* primary hairpin (negative control). MS analysis shows specific m7G methylation of the *let-7e* hairpin. The average of three independent experiments ± SDs is shown.(F) Experimental strategy to obtain radiolabeled, m7G-modified *pri-let-7e* (*IVm7G-pri*). The histogram shows the fraction of RNA recovered by m7G-RIP after *in vitro* methylation with METTL1/WDR4, as evaluated by scintillation counting (^∗∗∗^p \< 0.001, two-tailed t test).(G) *In vitro* processing assay of *pri-let-7e*: control (Ctrl) or *in vitro* methylated pri-miRNAs were incubated in the presence of immunoprecipitated DROSHA. Autoradiography reveals that *IVm7G-pri* undergoes more efficient processing, yielding the expected cleavage pattern shown in the illustration. The histogram shows the relative quantification of the resulting *pre-let-7e* from four samples obtained in two independent experiments (^∗^p \< 0.05, two-tailed t test). Autoradiography images are composites of different molecular weight regions and exposure times. Full, unprocessed images are deposited on Mendeley Data.See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

The above findings indicate that METTL1 activity is required for pri- to pre-processing of miRNAs, implying that pri-miRNAs are directly m7G modified by METTL1 and that the modification is subsequently retained through to the mature miRNA ([Figure S4](#mmc1){ref-type="supplementary-material"}H). m7G RIP experiments show that pri-miRNAs are enriched in m7G, which decreases upon *METTL1* knockdown ([Figures 4](#fig4){ref-type="fig"}D, [S4](#mmc1){ref-type="supplementary-material"}I, and [S4](#mmc1){ref-type="supplementary-material"}J).

To further demonstrate the METTL1-dependent effect on miRNA processing, we used an *in vitro* assay ([@bib36]) to test the efficiency of cellular extracts to process a radioactive *pri-let-7e* transcript into precursor and mature miRNAs. Cellular extracts devoid of METTL1 process precursor transcripts less efficiently than control extracts ([Figure S5](#mmc1){ref-type="supplementary-material"}A). Thus, METTL1 is required for the efficient processing of target miRNAs such as *let-7*.

To confirm that *pri-let-7e* is directly methylated by METTL1, we performed an *in vitro* methyltransferase assay using a pre-assembled recombinant METTL1/WDR4 complex ([Figure S5](#mmc1){ref-type="supplementary-material"}B) and *pri-let-7e* hairpin oligonucleotides, tRNA^Phe^, and an unrelated negative control miRNA (*cel-miR-67* hairpin) as substrates. Using MS, we detected m7G in *let-7e* RNA and tRNA^Phe^, but not in the control miRNA ([Figures 4](#fig4){ref-type="fig"}E and [S5](#mmc1){ref-type="supplementary-material"}C).

To directly assess whether m7G affects miRNA processing, we prepared radiolabeled m7G containing *pri-let-7e* RNA, as shown in [Figure 4](#fig4){ref-type="fig"}F. Briefly, radioactive *pri-let-7e* hairpin RNA was methylated *in vitro* by incubation with the METTL1/WDR4 complex, and m7G containing RNA was enriched via RIP. The resulting methylated and non-methylated (control) pri-miRNAs were then subjected to a DROSHA processing assay. The results indicate that m7G methylated *pri-let-7e* RNA was more efficiently processed by DROSHA *in vitro* ([Figure 4](#fig4){ref-type="fig"}G).

To probe the mechanism by which m7G methylation of *let-7e* affects its processing *in vivo*, we sought to identify the position of the methylation site within the *let-7e* miRNA. We set up spectral sequencing of RNA methylation and applied it to mature miRNAs purified from A549 cells. This targeted MS method allows the mapping of modification sites within a specific sequence at single base resolution. This approach highlighted one methylated guanosine at position 11 (G11) of *let-7e-5p* ([Figures 5](#fig5){ref-type="fig"}A, 5B, and [S5](#mmc1){ref-type="supplementary-material"}D), which is also required for efficient *in vitro* methylation of *let-7e* ([Figure S5](#mmc1){ref-type="supplementary-material"}E).Figure 5G-Quadruplexes Mark m7G-Containing miRNAs(A and B) Spectral sequencing of *in vivo let-7e-5p* showing unmodified (A) and methylated 5′-AGGAGGU-3′ (B) fragments, obtained following RNase A digestion of a miRNA fraction isolated from A549 cells (see also [Figure S5](#mmc1){ref-type="supplementary-material"}).(C) Boxplot showing the maximum G-score, a quantitative estimation of G-richness and G-skewness (see [Method Details](#sec4.4){ref-type="sec"} for definition), in primary hairpins of either unmodified or m7G containing miRNAs (^∗∗∗^p \< 0.001, Wilcoxon test).(D) Boxplot showing the enrichment of miRNAs, grouped according to the propensity of their primary hairpins to form G-quadruplexes (^∗∗∗^p \< 0.001, Wilcoxon test).(E) Metagene plot showing pri-miRNA cleavage site distribution (top) and the predicted stability of G-quadruplexes (center), and double strand (bottom) across primary hairpins of unmodified (gray) or m7G-modified miRNAs (blue).(F) Denaturation experiments of *let-7e* primary hairpin in the presence of 100 mM KCl followed by circular dichroism at 263 or 210 nm show two transitions demonstrating that *let-7e* exists as a mixture of two distinct structures in equilibrium in solution (top). The first structure melts at 48.5°C--50.6°C, while the second one is more stable (75.9°C--73.6°C).(G) Scheme showing the predicted G-quadruplex (rG4, pink) within the *pri-let-7e* hairpin. In red are shown the guanosines predicted to be involved in the formation of the quadruplex motif. Arrows mark the cleavage sites of *let-7e-5p* processing. The asterisk indicates the position of m7G.See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

G11 is part of a short 16-nt-long G-rich sequence of the form G~2+~N~4~G~2+~N~4~G~2+~N~4~G~2+~, where N is any base. This type of motif is known to fold into the alternative Hoogsteen base-paired G-quadruplex structure ([@bib31]). It is noteworthy that the formation of a G-quadruplex structure has been documented in three miRNA precursors, namely *miR-92b* ([@bib48]), *miR-149* ([@bib32]), and *let-7e* ([@bib50]). According to our previous results, all of these miRNAs are both m7G modified and METTL1 dependent ([Table 1](#tbl1){ref-type="table"}), suggesting that G-quadruplex formation may be involved in the regulation of m7G-modified miRNAs.

To explore the connection between G-quadruplexes and m7G, we analyzed the base composition of m7G harboring miRNAs, assessing the potential enrichment of G-quadruplex motifs. We found that m7G-modified miRNAs are characterized by a bias in nucleotide content toward increased G-richness ([Figure S6](#mmc1){ref-type="supplementary-material"}A) and G-skewness ([Figure 5](#fig5){ref-type="fig"}C). These observations suggest that m7G harboring miRNAs display sequences with the propensity to form G-quadruplexes. Moreover, using a G-quadruplex-predicting algorithm, we found that miRNAs containing at least one predicted G-quadruplex are significantly enriched in m7G ([Figures 5](#fig5){ref-type="fig"}D and [S6](#mmc1){ref-type="supplementary-material"}B). The G-quadruplexes are predicted to fold at a very similar relative position within different m7G-containing miRNA hairpins ([Figure 5](#fig5){ref-type="fig"}E), which overlaps the 5′ site of pri-miRNA (DROSHA) cleavage. Overall, these analyses suggest that G-quadruplexes contribute to the METTL1-mediated regulation of miRNA activity.

To support a role for G-quadruplex formation in the processing of *pri-let-7e*, we carried out a biophysical analysis of the short 16-nt-long G-rich sequence, referred to as *rG4-let-7e*. Using circular dichroism (CD), we found that the CD spectrum of *rG4-let-7e* is cation dependent and is characterized by a maximum ellipticity at 263 nm and a minimum ellipticity at 240 nm ([Figure S6](#mmc1){ref-type="supplementary-material"}C). This observation is consistent with G-quadruplex formation ([@bib33]). Denaturation experiments revealed a potassium-dependent transition at 48.1°C ([Figure S6](#mmc1){ref-type="supplementary-material"}C). We then assessed the ability of this sequence to fold into a G-quadruplex in the context of *pri-let-7e*. The CD spectrum of *pri-let-7e* also displayed a maximum at 263 nm and a local minimum at 240 nm, but with an additional minimum at 210 nm indicative of a more complex structure ([Figure S6](#mmc1){ref-type="supplementary-material"}D). Denaturation experiments of *pri-let-7e*, followed by CD spectroscopy at 263 or 210 nm in the presence of KCl, revealed two transitions indicating the presence of two structures in equilibrium ([Figure 5](#fig5){ref-type="fig"}F). While the second transition is centered around ∼75°C and correspond to the expected hairpin structure, a first transition was observed at ∼48°C, similar to the melting transition of *rG4-let-7e*, and may correspond to the formation of the *rG4-let-7e*-quadruplex structure. To support this point, we introduced G-to-A mutations in *pri-let-7e* at positions that are expected to destabilize the *rG4-let-7e*-quadruplex ([Figure S6](#mmc1){ref-type="supplementary-material"}E). We found that G-to-A mutants display single-phase melting curves with transitions \>70°C ([Figure S6](#mmc1){ref-type="supplementary-material"}F). This result demonstrates that G-to-A mutations in *pri-let-7e* impede G-quadruplex formation.

We hypothesized that m7G may affect the stability of G-quadruplexes *in vivo* by disrupting the N7 H-bonds and Hoogsteen base pairing while preserving Watson-Crick base pairing ([Figure 6](#fig6){ref-type="fig"}A). To support this hypothesis, we used 7-deaza-deoxyguanosine (DAG) as a mimic of m7G, since synthesis of m7G-containing oligonucleotides is currently unavailable and because, like m7G, DAG weakens secondary structures supported by Hoogsteen base pairing ([Figure 6](#fig6){ref-type="fig"}A; [@bib53]). We found that the *rG4-let-7e* quadruplex structure containing a single G-to-DAG substitution at the G11 position was significantly less stable than the WT sequence ([Figure S6](#mmc1){ref-type="supplementary-material"}C). We then generated G-to-DAG mutant versions of *pri-let-7e* ([Figure 6](#fig6){ref-type="fig"}B). While the D1 and D2 oligonucleotides displayed two G-to-DAG mutations at G4-G5 and G11-G12, respectively, one oligonucleotide bears a single G-to-DAG mutation at position G11. Denaturation experiments followed by CD spectroscopy were performed to assess the quadruplex:stem-loop equilibrium within *pri-let-7e* and the contribution of each guanosine to *pri-let-7e* folding ([Figures 6](#fig6){ref-type="fig"}C and 6D). We observed that mutation of G11 (in both D2 and G11 mutants) affects the folding of *pri-let-7e* by shifting the structural equilibrium toward the canonical stem-loop structure. In contrast, mutating G4 and G5 (D1 mutant) did not significantly affect the structural equilibrium. These results suggest that the methylation of G11 favors the stem-loop structure of *let-7e*.Figure 6m7G Position Is Essential for *let-7e* Quadruplex:Stem-Loop Equilibrium and Promotes miRNA Processing(A) Schematic representation of a guanine tetrad, highlighting Hoogsteen base pairing involving the N7 of guanosine that stabilizes the G-quadruplex structure, together with a stabilizing monovalent cation (M^+^, usually potassium). Both 7-methylguanosine and 7-deaza-guanosine are able to destabilize the hydrogen bond involving N7.(B) Illustration depicting the pri-miRNA hairpins used in the following experiments.(C) Thermal denaturation studies of RNA oligonucleotides as described in (B). While GG-to-DAG-DAG mutation at the D1 position does not significantly affect the contribution of G4 in the G4:stem-loop equilibrium, GG-to-DAG-DAG mutation at the D1 position and a single G11-to-DAG mutation affect the contribution of rG4 in the structural equilibrium by shifting it toward the hairpin form.(D) First derivative plot of the denaturation experiment in (C) helps visualize the decrease in rG4 contribution to the equilibrium (red arrow).(E) qRT-PCR showing the levels of *let-7e-5p* 72 h after transfection with either WT, D1, D2, or G11 oligonucleotides. The average of six independent transfections ± SDs is shown (^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, two-tailed t test).(F) Western blot showing the rescue of HMGA2 upregulation upon transfection of D2, but not WT *let-7e* primary hairpin in A549 *METTL1* knockdown cells. Two representative biological replicates of a total of three independent experiments are shown.

We next used the DAG-containing *pri-let-7e* hairpin oligonucleotides to establish whether the induced change in structure affects the processing of the precursor RNAs *in vivo*. We transfected either WT or the DAG-containing oligonucleotides into A549 cells and we measured the levels of mature *let-7e-5p* by qRT-PCR 72 h after transfection. Furthermore, we transfected D2 and WT oligonucleotides into A549 *METTL1* knockdown cells and measured the levels of HMGA2 by immunoblotting. In agreement with the biophysical observations, the D2 oligonucleotides, containing G11 DAG, were more efficiently processed than either WT *let-7e* or D1 oligonucleotides ([Figure 6](#fig6){ref-type="fig"}E). Finally, the D2 oligonucleotide effectively rescued HMGA2 expression in the absence of METTL1, whereas the WT did not ([Figure 6](#fig6){ref-type="fig"}F). Overall, our data suggest that the methylation of *pri-let-7e* at G11 promotes its processing via disruption of local G-quadruplex structures.

Discussion {#sec3}
==========

In the present study, we use two independent unbiased techniques to demonstrate that a subset of miRNAs harbors internal m7G modification. We find that these are functionally related, tumor-suppressive miRNAs, and they include the *let-7* family. We show that m7G promotes the processing of their precursor RNAs and that METTL1-dependent methylation is required to suppress cellular migration. Furthermore, we developed a new MS approach to identify m7G within a sequence-specific context using RNA purified from cells. This allowed us to pinpoint the modification to G11 of the mature *let-7e-5p*. We show that *pri-let-7e* can adopt two alternative conformations, which are consistent with a G-quadruplex structure and a canonical stem-loop. The G11 position has previously been implicated in the formation of a G-quadruplex structure ([@bib50]), and we confirm the presence of this G-quadruplex in *let-7e.* We show that the substitution of G11 with DAG affects the quadruplex:stem-loop equilibrium within *pri-let-7e* and mimics the effects due to m7G.

The presence of m7G in miRNAs strongly correlates with their predicted tendency to adopt G-quadruplex structures. Such structures are known to be inhibitory to miRNA processing ([@bib48], [@bib50]), which is consistent with our findings that the G-quadruplex motif in *let-7e* overlaps the DROSHA cleavage site. Our data suggest a model in which METTL1-mediated deposition of m7G within G-rich regions destabilizes G-quadruplexes, thereby promoting their processing from pri- to pre-miRNA ([Figure 7](#fig7){ref-type="fig"}).Figure 7Role of m7G in miRNA BiogenesisProposed model of the role of METTL1-mediated m7G in promoting miRNA processing and suppressing migration phenotype.

While this manuscript was under revision, Gregory and colleagues ([@bib40]) reported that *METTL1* knockout mouse embryonic stem cells possess defective mRNA translation at a global level. In our system, by using an inducible knockdown approach to reduce the levels of METTL1, we did not dramatically affect the levels of m7G in tRNAs ([Figure S2](#mmc1){ref-type="supplementary-material"}G). This is consistent with our ribosome profiling results in normal versus METTL1-depleted cells, which showed no significant effect on overall translation ([Figure S2](#mmc1){ref-type="supplementary-material"}K). Therefore, our inducible approach allowed us to dissect new, orthogonal, m7G-dependent pathways, uncoupling them from the effects of tRNA.

G-quadruplexes and other alternative structures involving non-Watson-Crick base pairing have been described in other classes of RNA, including mRNA ([@bib9]); there they are proposed to induce ribosome stalling, thereby inhibiting translation ([@bib22]). We speculate that m7G represents a general way of destabilizing such structures, counteracting their effects. Thus, a comprehensive understanding of the m7G modification pathways will be instrumental in deciphering the roles that Hoogsteen-based structures play in physiological and pathological settings.

Only two other miRNA methylations have been identified in miRNAs, m6A and 5′-methyl phosphate ([@bib1], [@bib63]). However, these two modifications show features that are different from the m7G features characterized here. On the one hand, m6A enhances processing of many, if not all, miRNAs in breast cancer cells, and can be regarded as a general mechanism; this methylation promotes the binding of DROSHA to the primary miRNA. On the other hand, 5′-methyl phosphate represses the processing of *miR-145* by inhibiting the binding of DICER to the pre-miRNA. Here, we show that m7G promotes miRNA processing in a unique manner, by directly affecting the secondary structure of a specific set of pri-miRNAs that share a common functional signature: suppression of cell migration.

The model proposed here could represent a widespread molecular mechanism to safeguard the levels and activity of important tumor-suppressive G-rich miRNAs. In this scenario, the formation of G-quadruplexes is a "side effect" of the miRNA sequence, and the m7G pathway is required to maintain pre-miRNAs in a functional state. Alternatively, but not mutually exclusively, the presence of G-quadruplexes itself may represent a novel additional layer of regulation to control functionally related miRNAs, which, for example, inhibit cell migration.

Many mechanisms control cell migration and tumor invasiveness, and one of the most important drivers is the AKT oncogenic signaling pathway ([@bib28]). Notably, AKT has been shown to directly phosphorylate METTL1 to inhibit its enzymatic activity ([@bib12]). Given the findings presented here, it is likely that the hyperactivation of AKT in cancer would reduce the levels of m7G-containing tumor-suppressive miRNAs, including the *let-7* miRNA family. This family in particular inhibits the progression and invasiveness of numerous tumors, including lung cancer, by regulating the expression of key oncogenes such as *RAS*, *MYC*, and *HMGA2* ([@bib3]). The control of *let-7* family members by the m7G pathway may represent a common mechanism to modulate their expression and therefore activity. Beyond cancer, *let-7* is implicated in neurodegenerative diseases, such as Alzheimer's disease, in which it is significantly upregulated ([@bib38]). Furthermore, low levels of *let-7* have been shown to improve tissue repair through reprogramming cellular metabolism ([@bib47], [@bib57]). Therefore, direct targeting of METTL1 could represent a valid and unexplored therapeutic strategy in these pathological contexts.

This report identifies the m7G pathway as a novel regulator of miRNA function. Considering the interest in miRNA as targets and tools in therapeutic intervention ([@bib13]), our findings could be exploited in many miRNA-related disease settings to open up new therapeutic avenues.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Anti-m7G Mouse MonoclonalMBL (RN017M)RRID: [AB_2725740](nif-antibody:AB_2725740){#intref0010}Anti-METTL1 Rabbit PolyclonalAbcam (ab157097)RRID: [AB_2725741](nif-antibody:AB_2725741){#intref0015}Anti-METTL1 Sheep Polyclonal (for IP)MRC PPU (588192)RRID: [AB_2725742](nif-antibody:AB_2725742){#intref0020}Anti-HMGA2 Rabbit PolyclonalAbcam (ab202387)RRID: [AB_2725743](nif-antibody:AB_2725743){#intref0025}Anti β-Tubulin Rabbit PolyclonalAbcam (ab6046)RRID: [AB_2210370](nif-antibody:AB_2210370){#intref0030}IgG Rabbit Isotype ControlAbcam (ab171870)RRID: [AB_2687657](nif-antibody:AB_2687657){#intref0035}Anti-FLAG tag Mouse MonoclonalSigma-Aldrich (F1804)RRID: [AB_262044](nif-antibody:AB_262044){#intref0040}Anti-6xHIS tag Rabbit PolyclonalAbcam (ab9108)RRID: [AB_307016](nif-antibody:AB_307016){#intref0045}Anti-Myc tag Mouse MonoclonalAbcam (ab32)RRID: [AB_303599](nif-antibody:AB_303599){#intref0050}Anti-Rabbit IgG HRP-conjugated Goat PolyclonalAbcam (ab6721)RRID: [AB_955447](nif-antibody:AB_955447){#intref0055}Anti-Mouse IgG HRP-conjugated Goat PolyclonalDako (P0447)RRID: [AB_2617137](nif-antibody:AB_2617137){#intref0060}**Bacterial and Virus Strains**TOP10 Chemically Competent *E. coli*Thermo FisherCat\# C404003**Chemicals, Peptides, and Recombinant Proteins**1,1,1,3,3,3-Hexafluoropropan-2-olApollo ScientificCat\# PC08771,4-DithiothreitolThermo FisherCat\# P23252-MercaptoethanolSigma-AldrichCat\# M31487-methylguanosine triphosphateSigma-AldrichCat\# M6133Acetic AcidFisher ScientificCat\# A/0400/PB17AcetonitrileFisher ScientificCat\# 10407440Antarctic PhosphataseNEBCat\# M0289SAdenosine 5′-TriphosphateNEBCat\# P0756SBenzonaseSigma-AldrichCat\# E1014-25KUBoric AcidBDH Lab. SuppliesCat\# 100584SBovine Serum AlbuminNEBCat\# B9000SCacodylic acidSigma-AldrichCat\# C0125CapCLIP Acid PyrophosphataseCellScriptCat\# C-CC15011HChloroformFisher ScientificCat\# C/4960/15CycloheximideSigma-AldrichCat\# C7698Deoxycholic acidSigma-AldrichCat\# D2510DNAse IQiagenCat\# 79254DoxycyclineClontechCat\# 8634-1Ethylenediaminetetraacetic AcidFisher ScientificCat\# D/0700/53EthanolVWRCat\# 20820.327Ethidium BromideSigma-AldrichCat\# E1510FibronectinSigma-AldrichCat\# F2006Formaldehyde 37%Sigma-AldrichCat\# 252549Formic acidFisher ScientificCat\# 10596814G418 disulphateMelfordCat\# G0175GlycogenRocheCat\# 10901393001HEPESMelfordCat\# B2001KClSigma-AldrichCat\# P9333LiClSigma-AldrichCat\# L-4408Lipofectamine 2000Thermo FisherCat\# 11668019Lithium HydroxideSigma-AldrichCat\# 442410MethanolVWRCat\# 20846.326METTL1/WDR4 Recombinant complexEvotec(*Ad hoc* preparation)MgCl~2~Sigma-AldrichCat\# M-0250N-(aminooxyacetyl)-N'-(D-Biotinoyl) hydrazineThermo FisherCat\# A10550NaClSigma-AldrichCat\# S7653NheINEBCat\# R3131SNotINEBCat\# R3189SNP40Sigma-AldrichCat\# I3021Phenylmethanesulfonyl fluorideSigma-AldrichCat\# P7626Phosphocreatine disodium salt hydrateSigma-AldrichCat\# P7936Phosphodiesterase 1Sigma-AldrichCat\# P3243-1VLPolybreneSigma-AldrichCat\# 107689Protease Inhibitor Complete tablets, EDTA-freeRocheCat\# 11836170001Proteinase KNEBCat\# P8107SPuromycinInvivogenCat\# ant-pr-1QiazolQiagenCat\# 79306RNAse AThermo FisherCat\# EN0531RnaseOUT Ribonuclease InhibitorThermo FisherCat\# 10777019RNAsin Plus Ribonuclease InhibitorPromegaCat\# N2611S-Adenosyl-MethionineNEBCat\# B9003SSodium borohydrideSigma-AldrichCat\# 480886Sodium dodecyl sulfateICNCat\# 811030Sodium hydroxideSigma-AldrichCat\# S8045Spermidine trihydrochlorideSigma-AldrichCat\# S2501SucroseFisher ScientificCat\#S/8600/60TriethylamineVWRCat\# 84883.180TRIS BaseMelfordCat\# T60040-1000.0Triton X-100Sigma-AldrichCat\# X100Tween-20Sigma-AldrichCat\# P1379Uridine-^13^C9,^15^N2 5′-triphosphateSigma-AldrichCat\# 645672-1MGXbaINEBCat\# R0145S\[α-^32^P\]-GTP / 3000Ci/mmol - 10mCi/mlPerkin-ElmerCat\# BLU006H250UC**Critical Commercial Assays**Agilent SurePrint G3 Human Gene Expression Array v3 (8x60K)Agilent TechnologiesCat\# G4851CDual-Glo Luciferase Assay SystemPromegaCat\# E2920ECL Prime detection reagent kitGE HealthcareCat\# RPN2232Fast SybrGreen PCR mastermixApplied BiosystemsCat\# 4385612High-capacity cDNA reverse transcription kitApplied BiosystemsCat\# 4368814Low Input QuickAmp Labeling Kit, One-ColorAgilent TechnologiesCat\# 5190-2305miRNEasy mini kitQiagenCat\# 217004miScript II RT kitQiagenCat\# 218161NEBNext SmallRNA kitNEBCat\# E7300SQubit dsDNA HS Assay KitThermo FisherCat\# Q32851Qubit RNA HS AssayThermo FisherCat\# Q32852RNA Clean & Concentrator - 25ZymoCat\# R1017RNA Clean & Concentrator - 5ZymoCat\# R1013RNeasy MinElute Cleanup KitQiagenCat\# 74204SuperScript III Reverse TranscriptaseThermo FisherCat\# 18080044Tapestation RNA ScreenTapeAgilent TechnologiesCat\# 5067-5576TaqMan Advanced miRNA cDNA Synthesis KitThermo FisherCat\# A28007TaqMan Fast Advanced Master MixApplied BiosystemsCat\# 4444556TaqMan Advanced miRNA Assay (A25576)Thermo FisherListed in [Table S8](#mmc1){ref-type="supplementary-material"}TranscriptAid T7 High Yield KitThermo FisherCat\# K0441Universal ProbeLibrary (4683633001)RocheListed in [Table S8](#mmc1){ref-type="supplementary-material"}**Deposited Data**METTL1 Knockdown Expression Microarray dataThis studyGEO: [GSE112180](ncbi-geo:GSE112180){#intref0065}BoRed-seq and m7G-RIP-seq in A549This studyGEO: [GSE112181](ncbi-geo:GSE112181){#intref0070}m7G-RIP-Seq in Caco-2This studyGEO: [GSE120454](ncbi-geo:GSE120454){#intref0075}m7G-RIP-Seq in A549 METTL1 KnockdownThis studyGEO: [GSE120455](ncbi-geo:GSE120455){#intref0080}Unprocessed imaging dataThis study<https://data.mendeley.com/datasets/yscng45zgj/1>**Experimental Models: Cell Lines**HEK-293T (Human embryonic kidney)ATCCRRID: CVCL_0063A549 (Human lung adenocarcinoma)ATCCRRID: CVCL_0023Caco-2 (Human colorectal adenocarcinoma)ATCCRRID: CVCL_0025**Oligonucleotides**DNA and RNA oligonucleotides are listed in Table S8This studyN/A*GFP* MISSION esiRNAsSigma-AldrichCat\# EHUEGFP-50UG*METTL1* MISSION esiRNAsSigma-AldrichCat\# EHU076851-50UGmiRIDIAN Control miRNA mimicDharmaconCat\# CN-001000-01-05miRIDIAN *hsa-let-7e-5p* miRNA mimicDharmaconCat\# C-300479-05-0002**Recombinant DNA**Hmga2-Luc-m7Addgene\#14788Hmga2-Luc-wtAddgene\#14785PAX2Addgene\#12260pcDNA3-pri-let-7eAddgene\#51380pcDNA4/TO/cmycDroshaAddgene\#10828pHIV-ZsGreenAddgene\#18121pLKO-TETon-PuroAddgene\#21915pMD2.GAddgene\#12259pMirGloPromegaCat\# E1330**Software and Algorithms**Bioconductor<https://www.bioconductor.org/>N/ADESeq2[@bib42]N/AFastQC<https://github.com/s-andrews/FastQC>N/AfeatureCounts[@bib39]N/AG4Hunter[@bib7]N/AGage[@bib43]N/Agbm[@bib24]N/Alimma[@bib59]N/AmiRWalk 2.0[@bib21]N/APathwiew[@bib44]N/AQuadparser[@bib27]N/AR statistical environment<https://www.r-project.org/>N/ARNAfold[@bib41]N/ASTAR[@bib18]N/ASylamer[@bib62]N/ATrimmomatic[@bib8]N/AFeature Extraction SoftwareAgilent TechnologiesG4463AAXCaliburThermo FisherOPTON-30487**Other**ACQUITY UPLC HSS T3 ColumnWaters CorpCat\# 186005614Amicon 30kDa MWCO spin-columnMerck MilliporeCat\# Z717185Amersham Hybond-C Extra Nitrocellulose membraneGE HealthcareCat\# RPN203DAmersham Hybond-N+ Nylon MembraneGE HealthcareCat\# RPN2020BAmersham Hyperfilm HS autoradiography filmGE HealthcareCat\# 28906836Bradford assayBio-RadCat\# 5000006Denhart's solutionThermo FisherCat\# 750018Dulbecco's Modified Essential MediumGibcoCat\# 41965-039Dynabeads MyOne Streptavidin C1Thermo FisherCat\# 65001Dynabeads Protein GThermo FisherCat\# 10004DEagle's Modified Essential MediumSigma-AldrichCat\# M2279Fetal Bovine SerumGibcoCat\# 10270-106Illustra MicroSpin G-25 spin columnGE HealthcareCat\# 27532501Migration assay transwell inserts (8 μm)CorningCat\# [3422](mi:3422){#intref0105}Novex TBE 6% precast gelThermo FisherCat\# EC6265BOXNovex TBE-Urea 10% precast gelThermo FisherCat\# EC6875BOXNovex TBE-Urea 15% precast gelThermo FisherCat\# EC6885BOXNovex TBE-Urea 6% precast gelThermo FisherCat\# EC6865BOXNovex TBE-Urea Sample BufferThermo FisherCat\# LC6876Penicillin/Streptomycin/GlutamineGibcoCat\# 10378016Protein G Sepharose 4 Fast Flow beadsGE HealthcareCat\# 17-0618-01

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Queries and reagent requests may be directed and will be fulfilled by the lead contact, Tony Kouzarides (<tony.kouzarides@gurdon.cam.ac.uk>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Cell lines {#sec4.3.1}

HEK293T (RRID:CVCL_0063) and A549 cells (RRID:CVCL_0023) were cultured in DMEM (Invitrogen), supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin/glutamine (PSQ). Caco-2 cells (RRID:CVCL_0025) were cultured in Eagle's Minimum Essential Medium, supplemented with 20% FBS and 1% PSQ. Cell lines were obtained from the ATCC and tested negative for mycoplasma contamination. Human cell lines used are not listed in the cross-contaminated or misidentified cell lines database curated by the International Cell Line Authentication Committee (ICLAC).

### Lentiviral vector preparation and cell transduction {#sec4.3.2}

For virus production, HEK293T cells were transfected with the lentiviral vector pLKO-TETon-Puro for *METTL1* knockdown, or Zs-Green-HIV for *METTL1* rescue experiments, together with the packaging plasmids PAX2 (Addgene Plasmid \#12260) and pMD2.G (Addgene Plasmid \#12259) at a 1:1.5:0.5 ratio using Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's instructions. Supernatants were harvested 48 h and 72 h after transfection. Cells (5 × 10^5^) were mixed in 2 ml viral supernatant supplemented with 8 μg/ml polybrene (Millipore), followed by spinfection (60 min, 900 g, 25°C) and further incubated overnight at 37°C. For *METTL1* knockdown experiments, cells were replated in fresh medium containing 1 μg/ml puromycin and kept in selection medium for 7 days. For METTL1 rescue experiments, GFP+ cells were isolated using a SONY SH800 cell sorter 48 h after infection.

### Generation of conditional knockdown cells {#sec4.3.3}

A549 or Caco-2 cells were infected with pLKO-TETon-Puro lentiviral vectors (Addgene Plasmid \#21915) expressing shRNAs against the coding sequence of human *METTL1* or a scrambled control as described above. The shRNA sequences are listed in [Table S8](#mmc1){ref-type="supplementary-material"}. shRNA was induced by treatment with 200 ng/ml doxycycline for the indicated times.

Method Details {#sec4.4}
--------------

### BoRed-Seq and m7G-RIP-Seq {#sec4.4.1}

The detailed protocol of all the procedures required to perform BoRed-Seq and m7G RNA immunoprecipitation experiments on small RNAs is described in [Methods S1](#mmc1){ref-type="supplementary-material"}. Single-end 50-bp stranded smallRNA libraries were prepared using the NEBNext SmallRNA kit (NEB) according to the manufacturer's recommendations and sequenced on a HiSeq 4000 (Illumina).

### RNA immunoblots and dot blots {#sec4.4.2}

RNA was resolved by denaturing polyacrylamide gel electrophoresis using Novex TBE-urea 15% precast gels (Thermo Fisher). Equal loading was checked by staining with ethidium bromide (Sigma-Aldrich), then RNA was transferred to a nylon membrane (Amersham Hybond-N+, GE Healthcare) by wet electro-blotting in TBE (45 min at 400 mA).

For dot-blot analysis, input RNA or RNA immunoprecipitated with either anti-m7G or isotypic non-specific antibodies was spotted onto a nitrocellulose membrane and UV cross-linked at 254 nm (120 mJ/cm^2^). The membranes were blocked in Denhart's solution (1% Ficoll, 1% polyvinylpyrrolidone, 1% bovine serum albumin; Thermo Fisher) for 1 h at room temperature and incubated with m7G antibody for 1 h at room temperature. Signal was detected using HRP conjugated secondary antibodies and ECL (GE Healthcare) and developed on a Chemidoc MP machine (BioRad).

### Global gene expression profiling {#sec4.4.3}

Cells were lysed in Qiazol (QIAGEN) and total RNA was extracted with miRNeasy mini kit (QIAGEN). RNA quality was assessed using an Agilent Tapestation RNA; 50 ng of RNA were labeled with Low Input QuickAmp Labeling Kit, One-Color (Agilent Technologies), purified and hybridized overnight onto an Agilent SurePrint G3 Human Gene Expression Array v3 (8x60K) before detection according to the manufacturer's instructions. An Agilent DNA microarray scanner (model G2505C) was used for slide acquisition.

### RT-qPCR {#sec4.4.4}

Cells were lysed in Qiazol (QIAGEN) and total RNA was purified using the miRNEasy mini kit (QIAGEN) according to the manufacturer's instructions. For mRNA detection, 1 μg of purified total RNA was reverse transcribed using the high-capacity cDNA reverse transcription kit (Applied Biosystems). To quantify gene expression, we used probes from Universal ProbeLibrary (UPL; Roche) with TaqMan Fast Advanced Master Mix (Thermo Fisher).

For specific pri- and pre-miRNA quantification, we size-fractionated large (\> 200nt, containing the pri-miRNAs) and small RNAs (\< 200nt, containing pre-miRNAs) using RNA Clean & Concentrator 5 column kits (Zymo), as per the manufacturer's instructions. Pri-miRNAs were reverse transcribed using the High-Capacity cDNA reverse transcription kit (Applied Biosystems), which employs random nonamer priming and favors long molecules. Pre-miRNAs were reverse transcribed with miScript II RT kit (QIAGEN), which is more efficient on short RNAs. Primers were designed to anneal either within the stem loop (pre-miRNAs) or to overlap the DROSHA cleavage sites (pri-miRNAs). Both pri- and pre-miRNAs were quantified using Fast SybrGreen PCR mastermix (Applied Biosystems) according to the manufacturer's instructions.

For mature miRNA detection, total RNA was reverse transcribed and amplified using the Taqman Advanced miRNA cDNA Synthesis Kit from Thermo Fisher Scientific. The levels of specific miRNAs were measured with Taqman advanced miRNA Assays from Thermo Fisher Scientific. All the RT-qPCR experiments were run on an ABI 7900 real-time PCR machine (Applied Biosystems). *GAPDH* and *RNY1* were used as housekeeping genes for RT-qPCR normalization of long and small RNAs, respectively. Primer sequences, UPL probe numbers and assay IDs are listed in [Table S8](#mmc1){ref-type="supplementary-material"}.

### Western blotting {#sec4.4.5}

For total cell protein extraction and western blot analysis, cells were lysed in a buffer containing 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Triton X-100, 0.5% deoxycholic acid, 0.1% sodium dodecyl sulfate, Complete protease inhibitor cocktail (Roche) and cleared by centrifugation. The protein concentration was determined by Bradford assay (Bio-Rad). Proteins were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane (Hybond-C Extra, GE Healthcare). Membranes were blocked with 5% milk proteins in TBST (50 mM Tris-HCl pH 7.6, 150 mM NaCl, 0.05% Tween-20), and probed with primary antibodies overnight. Membranes were then washed three times with TBST (15 min each) and probed with a HRP-conjugated secondary anti-rabbit antibody for 1 h. After three more washes, signal was detected using HRP conjugated secondary antibodies and ECL (GE Healthcare) and developed on a BioRad Chemidoc MP machine.

### Migration assays {#sec4.4.6}

For transwell migration assays, the lower surface of the transwell inserts (8 μm; Corning) was coated with human recombinant fibronectin (1 μg/ml, 1 h at RT; Sigma-Aldrich). A549 cells were serum-starved overnight and seeded (3 × 10^4^) in serum-free medium on transwell inserts. After 7 h incubation in wells containing DMEM+20% FBS, inserts were stained with crystal violet and cells on the lower surface were counted (blindly).

### Proliferation assays {#sec4.4.7}

4 days after shRNA induction, 10^5^ A549 *METTL1* knockdown or Ctrl cells were plated in each well of 6-well cell culture plates in normal culture medium. Cells were counted daily for the following three days using a Countess II cell counter (Thermo Fisher).

### Mature miRNA/hairpin transfection {#sec4.4.8}

20 pmol of *hsa-let-7e-5p* miRNA mimic or control miRNAs (miRIDIAN, Dharmacon) were transfected into 2.5 × 10^5^ A549 cells using 2 μL of Lipofectamine 2000 (Thermo Fisher). 10 pmol of *pri-let-7e* hairpins (Integrated DNA Technologies) were transfected into 1.5 × 10^5^ A549 cells using the same amount of Lipofectamine as above.

### Luciferase assay {#sec4.4.9}

A dual luciferase reporter harboring the 3′-UTR of mouse *Hmga2* was generated extracting the XbaI-NotI digestion fragments from either Hmga2-Luc-wt or Hmga2-Luc-m7 ([@bib46]; Addgene plasmids \#14785 and \#14788) and subcloning them into pMirGlo (Promega). In order to generate stable reporter lines, A549 cells were transfected with the pMirGlo-hmga2(3′-UTR) constructs. 24 h after transfection, cells were selected using 300 μg/ml G418 for 7 days. Subsequently, cells were transfected with 20 pmol of MISSION esiRNAs (Sigma-Aldrich) against human *METTL1* or GFP. 24 h after transfection, Firefly and Renilla luciferase activities were measured using the Dual-Luciferase Reporter Assay System (Promega) on a CLARIOstar microplate reader (BMG Labtech).

### METTL1 rescue experiments {#sec4.4.10}

cDNA was obtained by reverse transcription of A549 RNA with Superscript III (Thermo Fisher), then the *METTL1* full-length coding sequence was amplified by PCR and cloned into pHIV-ZsGreen plasmid (Addgene plasmid \#18121) using restriction sites XbaI and NotI. In order to generate an shRNA-resistant *METTL1* sequence, synonymous substitutions were introduced in the codons corresponding to shRNA binding sites by long DNA fragment synthesis (GeneArt Strings; Thermo Fisher) of the N-terminal portion of *METTL1* (up to NheI site). The *in vitro* synthesized fragment was swapped into pHIV-ZsGreen-METTL1 using restriction sites NotI and NheI. The same approach was combined to codon mutagenesis to generate the catalytically inactive METTL1 variant EIR/AAA (amino acids 107-109, that form the SAM-binding pocket of the enzyme; see [Figure S2](#mmc1){ref-type="supplementary-material"}I). Primer and long oligonucleotide sequences are listed in [Table S8](#mmc1){ref-type="supplementary-material"}.

### METTL1 UV-CLIP {#sec4.4.11}

Adherent cells in a 15 cm dish were rinsed twice in ice-cold PBS, cross-linked at 254 nm (120 mJ/cm^2^), scraped and lysed on ice for 10 min in 1 mL of fresh lysis buffer (25 mM Tris-HCl pH 8.0, 150 mM NaCl, 2 mM MgCl~2~, 0.5% NP-40, 5 mM DTT) supplemented with protease inhibitors (Complete tablets, Roche) and RNase inhibitors (RNaseOUT; Thermo Fisher). Lysates were vortexed, then centrifuged at max speed at 4°C for 5 min. The supernatants were used in immunoprecipitation (IP) assay with 5 μg of anti METTL1-antibody (sheep polyclonal obtained by MRC Protein Phosphorylation Unit, \#588192; [@bib12]) or control isotypic IgG at 4°C for 90 min, with rotation. 80 μL of Protein G Dynabeads (Invitrogen) per IP reaction were rinsed 2 times with lysis buffer and blocked with 1 mg/ml BSA (NEB) for 2 h at 4°C. Beads were resuspended in 100 μL lysis buffer, then added to the IP tube. The reaction was incubated at 4°C for 2 h with rotation. Beads were then washed twice with high-salt buffer (25 mM Tris-HCl pH 8.0, 500 mM NaCl, 1 mM MgCl~2~, 1% NP-40, 5 mM DTT) and three times with lysis buffer. Immunoprecipitated samples were treated with DNase I (QIAGEN) followed by digestion with Proteinase K (NEB). RNA was purified using an RNeasy MinElute column kit (QIAGEN).

### Expression and purification of recombinant METTL1/WDR4 (Evotec) {#sec4.4.12}

The constructs EV4866 (his-METTL1) and EV4868 (flag-WDR4) were cloned into plasmid pTriIJ-HV (Evotec). Recombinant virus was produced by co-transfecting transfer plasmid DNA and bacmid DNA in insect cells. 100 ng bacmid DNA and 500 ng transfer plasmid DNA were mixed with 2 μl Cellfectin II transfection reagent (Invitrogen) in 200 μl TC100 media (Sigma) and incubated at room temperature for 2-3 h. Sf21 insect cells, grown to 80%--90% confluency in 24 well plates were washed with TC100 before adding 0.2 mL TC100 and 0.2 mL co-transfection mix. After overnight incubation, 0.6 mL Sf900 II SFM media containing 5 μg/ml gentamicin was added and the cells were incubated at 27°C for six days with humidity. The cells were observed under an inverted microscope and compared to the mock-transfected control. BluoGal (2%) was added to the LacZ positive control well and blue coloration was observed within 1 h. Following confirmation of successful transfection, the medium containing the recombinant virus (P0) was harvested into a sterile deep well block and stored in the dark at 4°C. P1 BIICs (baculovirus-infected insect cells) were amplified in a sterile 24-deep well block by infecting Sf21 cells grown in Sf900 II SFM media containing 5 μg/ml gentamicin with P0 virus. The infected cultures were incubated for 72-120 h at 27°C with shaking at 360 rpm. P1-BIICs were harvested by centrifugation of the block and virus supernatant was removed to a fresh block and stored at 4°C. The cells were then re-suspended in freezing mix (Sf900 II + 10% heat inactivated FBS + 10% DMSO) and frozen gradually to −80°C, in the block. Working P2-BIICs were amplified by infecting Sf21 cells grown in shake flasks at MOI-0.1 using P1-BIICs and incubated for 72 h. P2-BIICs were harvested by centrifugation and infected cells were resuspended in freezing media and stored at −80°C. Sf21 cells grown in Sf900 II SFM media plus 5 μg/ml gentamicin were infected with both EV4866 and EV4868 P2 BIICs at an MOI of 2 (1+1). The infected culture was incubated for 72 h at 27°C with shaking at 110 rpm, before harvesting by centrifugation and storing at −80°C. Thawed cells were lysed in 25 mM Tris-HCl pH 8.0, 300 mM NaCl, 1 mM TCEP, 5% glycerol, 0.25% CHAPS supplemented with Complete EDTA-free protease inhibitor tablets (Roche). Samples were homogenized for 20-30 s with an IKA Ultra-Turrax and sonicated in a Branson probe sonicator (cycles of 30 s on, 30 s off for 5 min at 40% amplitude). Samples were centrifuged at 45000 rpm for 50 min to remove insoluble material. Purification was carried out by sequential Ni-affinity and size-exclusion chromatography on an ÄKTA Xpress system (GE). Samples were bound to 1 mL HisTrap FF column, washed with 25 mM Tris-HCl pH 8.0, 300 mM NaCl, 1mM TCEP, 5% glycerol, 20 mM imidazole and eluted with a step elution over 20 CV of 25 mM Tris-HCl pH 8.0, 300 mM NaCl, 1 mM TCEP, 5% glycerol and 500 mM imidazole at a flow rate of 0.8 ml/min. This was followed by size-exclusion on a 16/60 S200 column (25 mM Tris-HCl pH 8.0, 300 mM NaCl, 1 mM TCEP, 5% glycerol) at a flow rate of 1 ml/min. Purified protein was analyzed by SDS-PAGE, western blotting and measurement of A260/A280 to estimate levels of contaminating nucleosides. Aliquoted protein was snap-frozen in liquid nitrogen and stored at −80°C.

### *In vitro* RNA methylation assays {#sec4.4.13}

Recombinant METTL1/WDR4 (300 nM; Evotec) was incubated for 2 h with S-adenosylmethionine (15 μM) and oligonucleotide (1 μM) in a Tris-HCl pH 8.0 buffer (20 mM) supplemented with 1 mM DTT and 0.01% Triton X-100.

### Mass spectrometry analysis of RNA nucleoside m7G modification {#sec4.4.14}

Nucleosides were prepared from enzyme-processed RNA by enzymatic digestion, using a cocktail of Benzonase (Merck), Phosphodiesterase 1 (Merck), and Antarctic Phosphatase (New England Biolabs) as described previously ([@bib61]). The reactions were filtered using an Amicon 30kDa MWCO spin-column (Merck) to remove protein and the filtrate was mixed with a 2x loading buffer containing 0.1% formic acid and an internal standard (^13^C-labeled uridine generated from 645672-1MG Merck KGaA, previously treated with Antarctic Phosphatase). The samples were loaded onto an ACQUITY UPLC HSS T3 Column, 100 Å, 1.8 μm, 1 mm X 100 mm (Waters Corp., Milford, MA, USA) and resolved using a gradient of 2%--10% acetonitrile in 0.1% formic acid over 10 min. Mass spectrometric analysis was performed in positive ion mode on an Orbitrap QExactive HF (Thermo Fisher, Waltham, MA, USA) mass spectrometer. Standard dilutions of all experimental nucleosides were prepared and analyzed in parallel. There were three technical replicates of each sample and the analytical processing was performed using XCalibur Software (Thermo Fisher).

### Mature miRNA isolation {#sec4.4.15}

Mature miRNA fraction was isolated from total RNA by gel extraction: RNA was denatured by incubation at 73°C for 3 min in 2X Urea Sample Buffer (Thermo Fisher) and run in a 10% TBE--urea precast polyacrylamide gel (Thermo Fisher) at 250V for 12 min. Gel was visualized by ethidium bromide staining and the region corresponding to the expected size of mature miRNAs was excised using a synthetic 20-nt RNA ruler. After breaking the gel, miRNAs were eluted in a sodium acetate buffer (0.3 M sodium acetate, pH 5.2, 5 mM EDTA, 0.1% sodium dodecylsulfate) by freeze-thawing once on dry ice and incubating at 4°C overnight. miRNAs were purified by ethanol precipitation.

### Context-specific mass spectrometry analysis of miRNA m7G modification {#sec4.4.16}

Oligonucleotides were prepared from miRNA fraction using RNase A (Thermo Fisher) and chromatographically separated by ion pair reverse phase chromatography (200 mM Hexafluoroisopropanol \[HFIP\], 8.5 mM triethylamine \[TEA\] in water as eluent A, and 100 mM HFIP, 4.25 mM TEA in methanol as eluent B). The oligonucleotides were resolved by a gradient of 2.5% to 20% B at 200 nl/min on Acclaim PepMap C18 solid phase (Thermo Fisher) and characterized by negative ion tandem LC-MS in a hybrid quadrupole -- orbitrap (QExactive HF, Thermo Fisher). Data were collected in data-dependent acquisition mode in pathfinding experiments before subsequent hybrid acquisition investigation. Full scan MS1 data were acquired between 700 and 3500 m/z and extracted ion chromatograms from these data were used for label-free quantification of oligonucleotides derived from *let-7*. MS2 data were collected in subsequent scan events for the same *let-7* oligonucleotides by targeted, multiplexed, data-independent acquisition on filtered precursor ion masses multiplexed from the double and triple charge states of unmodified and monomethylated AGGAGGU (m/z of 1180.158, 786.436, 1187.166 and 791.108, with a window of 3 m/z). Technical replicates of n = 3 were acquired, with MS2 ions matched with to within 5 ppm.

### Preparation of naive and *in vitro* methylated \[α-^32^P\]-pri-let-7e {#sec4.4.17}

Plasmid pcDNA3-pri-let-7e (Addgene \#51380; [@bib26]) linearized by digestion with XbaI (NEB) was used as a template for RNA *in vitro* transcription in the presence of \[α-^32^P\]-GTP (Perkin Elmer) using TranscriptAid T7 High Yield Kit (Thermo Fisher). The resulting RNA (369bp) was denatured by incubation at 73°C for 3 min in 2X Urea Sample Buffer (Thermo Fisher) and run in a 6% TBE--urea precast polyacrylamide gel (Thermo Fisher). The band corresponding to the expected size of *pri-let-7e* transcript was excised using autoradiography and, after breaking the gel, RNA was eluted as described above for mature miRNA isolation.

2.5 μg of ^32^P-labeled *pri-let-7e* (1 μM) were incubated for 3 h at 37°C in the presence of recombinant METTL1/WDR4 (300 nM) and S-adenosylmethionine (1 mM) in a methylation buffer (85 mM Tris-HCl pH 8.0, 1.4 mM DTT, 0.07 mM EDTA, 1 mM spermidine). Methylated *pri-let-7e* was isolated by immunoprecipitation using m7G-specific antibody, purified on RNA Clean & Concentrator - 5 columns (Zymo) and quantified by scintillation counting (Hidex 300 SL).

### Isolation of DROSHA by IP {#sec4.4.18}

Immunopurification of DROSHA and *in vitro* processing assays were performed according to a published protocol ([@bib36]). HEK293T cells transfected with pcDNA4/TO/cmycDrosha plasmid ([@bib34]; Addgene plasmid \#10828) were lysed after 48 h in buffer D (20 mM HEPES--KOH pH 7.9, 100 mM KCl, 0.2 mM EDTA, 0.5 mM DTT, 0.2 mM PMSF, 5% glycerol) by sonication (Bioruptor: 5 min; 30 s ON / 30 s OFF, 200W) followed by centrifugation. 2 mg of crude extract were incubated with 12 μg of anti-myc-tag antibody (Abcam) for 2 h at 4°C, then the recombinant enzyme was pulled-down with 30 μL Protein G Sepharose 4 Fast Flow beads (GE Healthcare) and washed 4 times in buffer D. Whole-cell extracts were prepared from control and *METTL1* knockdown A549 cells using the same lysis protocol as above.

### *In vitro* miRNA Processing Assays {#sec4.4.19}

For comparing the pri- to pre-miRNA processing efficiency by DROSHA, 30000 cpm (50-100 ng) of either naive or *in vitro* methylated *pri-let-7e* were incubated with 15 μL of DROSHA-IP beads, 6.4 mM MgCl~2~ and 1U/μl RNaseOUT RNase inhibitor (ThermoFisher) for 80 min at 37°C.

For evaluating the processing activity of METTL1 depleted cells, 10 μL of processing reaction containing 5 μL of whole-cell extract, 1 μL of solution A (32 mM MgCl~2~, 5 mM ATP, 200 mM creatine phosphate), 1 μL 32 mM S-adenosyl methionine, 1 U/μl RNase inhibitor (Thermo Fisher) and the labeled transcripts (10^4^-10^5^ c.p.m.) were incubated at 37°C for 120 min.

All processing reactions were purified with RNA Clean & Concentrator - 5 column kit (Zymo), measured and equalized by scintillation counting, resolved on a 6% TBE--urea precast polyacrylamide gel (Thermo Fisher) and developed by autoradiography exposing the dried gel on Amersham Hyperfilm high-sensitivity film (GE Healthcare).

### Circular dichroism spectroscopy {#sec4.4.20}

CD experiments were conducted on a Chirascan Plus spectropolarimeter. Oligonucleotide solutions were prepared at a final concentration of 10 μM (*rG4-let-7e* oligonucleotides) or 2.5 μM (*let-7e* hairpins) in 10 mM lithium cacodylate (pH 7.2) containing 1mM EDTA and supplemented with 100 mM of LiCl, NaCl or KCl. Oligonucleotides were annealed by heating at 95°C for 3 min and cooling the solutions at 4°C for 4 h. Scans were performed over the range of 200--320 nm at 5°C. Each trace was the result of the average of three scans taken with a step size of 1 nm, a time per point of 1 s and a bandwidth of 1 nm. A blank sample containing only buffer was treated in the same manner and subtracted from the collected data. The data were finally baseline corrected at 320 nm. Denaturation experiments were performed by heating the samples to 95°C using the stepped temperature ramping mode, a setting time of 10 s and with data collection every 1°C monitoring the CD signal at 263 and 210 nm. Differential melting curves (quantification of folded fractions) were obtained by subtracting the upper baseline to the signal and dividing by the difference between the upper and lower baseline. Melting temperatures (T~1/2~) values were extracted as the local minima of the first derivatives of a Boltzman or bi-phasic dose-response fittings of the differential curves.

### Polysome fractionation {#sec4.4.21}

Control or *METTL1* knockdown cells (n = 2) were treated 5 days after doxycycline induction with 0.1 mg/ml cycloheximide for 5 min at 37°C, then they were lysed and polysomes were fractionated on a sucrose gradient while measuring absorbance at 254 nm ([@bib49]).

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

### Bioinformatic analysis of smallRNA sequencing {#sec4.5.1}

Multiplexed reads were split on the basis of their barcodes using Illumina Basespace. Read quality was assessed using FastQC program (<https://github.com/s-andrews/FastQC>). Library adaptors were trimmed with Trimmomatic ([@bib8]), and reads were mapped to the human genome (NCBI GRCh38/hg38) with STAR ([@bib18]), using the parameters of ENCODE guidelines: *\--runThreadN 15 \--sjdbGTFfile /path/to/GENCODE_miRNA_subset.gtf \--alignEndsType EndToEnd \--outFilterMismatchNmax 1 \--outFilterMultimapScoreRange 0 \--outSAMtype BAM SortedByCoordinate \--outFilterMultimapNmax 10 \--outSAMunmapped Within \--outFilterScoreMinOverLread 0 \--outFilterMatchNminOverLread 0 \--outFilterMatchNmin 16 \--alignSJDBoverhangMin 1000 \--alignIntronMax 1* ([@bib16]). Reads were summarized using featureCounts ([@bib39]) according to miRbase22 annotation ([@bib29]) of mature miRNAs. Differential miRNA enrichment in either m7G-RIP or BoRed-Pulldown over input/control sample was evaluated through negative binomial Wald test with the R package DESeq2 ([@bib42]; n = 2 for BoRed-Seq; n = 5 for m7G-RIP-Seq experiments).

### Global gene expression analysis {#sec4.5.2}

Microarray spot analysis was performed with Feature Extraction software (Agilent Technologies). Data were background-corrected and quantile normalized among arrays using the Bioconductor package limma ([@bib58], [@bib59]). The statistical significance of differential gene expression was calculated with the empirical Bayes method implemented in limma. KEGG pathway ontologies over-represented in the subset of genes upregulated or downregulated upon *METTL1* knockdown were evaluated using the R package Gage ([@bib43], [@bib44]).

In order to identify the mRNAs that are predicted to be targets of selected miRNAs, we extracted the positive hits of at least 3 out of 6 *in silico* prediction algorithms (namely miRWalk, miRanda, miRDB, Pictar2, RNA22 and Targetscan) using miRWalk 2.0 web server ([@bib21]).

For unbiased analysis of miRNA seed sequences enriched in the top upregulated genes upon *METTL1* knockdown, we took advantage of the Sylamer online software ([@bib62]).

To produce a classification model predicting mRNA upregulation upon *METTL1* knockdown, we extracted the subset of genes expressed above the background (log~2~ Average expression \> 6). Genes displaying a log2FoldChange \> 1 and a FDR \< 0.05 were considered upregulated, and then a model employing the presence of putative miRNA target sites as predictors was generated by gradient boosting using R package gbm ([@bib24]).

### Bioinformatic prediction of G-quadruplexes {#sec4.5.3}

Stem-loop and mature miRNA sequences were recovered from miRBase ([@bib29]) release 22. These sequences were used to calculate the quantitative parameters used to describe the different miRNA features discussed in this manuscript. Base composition was assessed using a custom Python script. *G-score*, a quantitative estimation of G-richness and G-skewness, is based on the G4Hunter algorithm ([@bib7]). Briefly, each position in a sequence is given a score between −4 and 4. To account for G-richness, a single G is given a score of 1, in a GG sequence each G is given a score of 2; in a GGG sequence each G is given a score of 3; and in a sequence of 4 or more Gs each G is given a score of 4. To account for G-skewness, Cs are scored similarly but their values are negative. The Gscore is the maximum value obtained while scanning miRNA sequences using a 20nt window and averaging the score of each nucleotide over the considered window.

G-quadruplex forming motifs, G2N7, G2N3, G3N7 and G3N12 are sequences of the form G~2+~N~1--7~G~2+~N~1--7~G~2+~N~1--7~G~2+~, G~2+~N~1--3~G~2+~N~1--3~G~2+~N~1--3~G~2+,~ G~3+~N~1--7~G~3+~N~1--7~G~3+~N~1--7~G~3+~ and G~3+~N~1--12~G~3+~N~1--12~G~3+~N~1--12~G~3+~ respectively, where N is any base. G3N7 represents the strict definition of G4 forming sequences according to the Quadparser algorithm ([@bib27]). Other motifs represent the loose definition of G4 forming sequences ([@bib31]). The presence of each motif within miRNA sequences was assessed using the *re.finditer* function in custom python scripts.

RNA secondary structures were predicted using the RNAfold 2.2.10 algorithm of the ViennaRNA package ([@bib41]). RNAfold computes the minimum free energy (MFE) of optimal secondary structures via estimation of base pairing probabilities. MFEs of dsRNA secondary structures (ΔG^0^~dsRNA~) were computed at 37°C. MFEs of G4 secondary structures (ΔG^0^~G4~) were computed by subtracting MFEs obtained when considering G4 formation into the structure prediction algorithm to the previous values (ΔG^0^~G4~ = ΔG^0^~dsRNA~ - ΔG^0^~(dsRNA +\ G4)~). RNAfold was used to assess the stability of predicted RNA structures within miRNA sequences using a 20nt sliding window. m7G-containing miRNAs are the subset of miRNAs that have been enriched from the total population of miRNAs using both the BoRed-Seq and m7G-RIP-Seq protocols. Background is the rest of annotated miRNAs. For assessing the local enrichment of structures within m7G-containing precursor miRNAs, pre-miRNA sequences were piled up and centered, MFE values were then averaged at each position. Data were compiled and plotted using R.

### Statistical analysis {#sec4.5.4}

All general statistical analyses were performed using either a two-tailed Student's t test or a Wilcoxon test (when distributions were assessed not to be normal and homoscedastic) at a confidence interval of 95%, unless otherwise specified. No statistical methods were used to predetermine sample size.

Data and Software Availability {#sec4.6}
------------------------------

### Data Resource {#sec4.6.1}

Raw genomic data have been deposited in the Gene Expression Omnibus database with accession number [GSE112182](ncbi-geo:GSE112182){#intref0120} (Expression Microarray data: [GSE112180](ncbi-geo:GSE112180){#intref0125}; BoRed-seq and m7G-RIP-seq in A549: [GSE112181](ncbi-geo:GSE112181){#intref0130}; m7G-RIP-Seq in Caco-2: [GSE120454](ncbi-geo:GSE120454){#intref0135}; m7G-RIP-Seq in A549 *METTL1* knockdown: [GSE120455](ncbi-geo:GSE120455){#intref0140}). Unprocessed imaging data are deposited on Mendeley Data: (<https://data.mendeley.com/datasets/yscng45zgj/1>). All other data and analysis scripts are available from the corresponding author upon reasonable request.
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